West German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment

Journal of Clinical Oncology

Volumn 34, Issue 20, 2016, Pages 2341-2349

  Gluz, Oleg ^a   Nitz, Ulrike A ^a   Christgen, Matthias ^b   Kates, Ronald E ^a   Shak, Steven ⁿ   Clemens, Michael ^c   Kraemer, Stefan ^d   Aktas, Bahriye ^e   Kuemmel, Sherko ^f   Reimer, Toralf ^g   Kusche, Manfred ^h   Heyl, Volker ⁱ   Lorenz Salehi, Fatemeh ^j   Just, Marianne ^k   Hofmann, Daniel ^a   Degenhardt, Tom ^l   Liedtke, Cornelia ^a,m   Svedman, Christer ⁿ   Wuerstlein, Rachel ^a,l   Kreipe, Hans H ^b   Harbeck, Nadia ^a,l   more..

^a Evangelical Hospital Bethesda   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Clinic of Nuclear Medicine   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f Hospital Essen Mitte   (Germany)

^g Suedstadt Hospital of Rostock   (Germany)

^h Marien Hospital Aachen   (Germany)

ⁱ Asklepios Paulinen Clinics   (Germany)

^j Asklepios Paulinen Clinics ^*  (Germany)

^k Oncologic Practice   (Germany)

^l UNIVERSITY OF MUNICH   (Germany)

^m UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁿ Genomic Health   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

21 GENE RECURRENCE SCORE ASSAY; ARTICLE; ASSAY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TRANSLATIONAL RESEARCH; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84977492898     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.5383     Document Type: Article

References (31)

1. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
2. Curtis C, Shah SP, Chin S-F, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352, 2012
3. Gluz O, Hofmann D, Würstlein R, et al: Genomic profiling in luminal breast cancer. Breast Care (Basel) 8:414-422, 2013
4. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
5. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A Trans ATAC study. J Clin Oncol 28:1829-1834, 2010
6. Habel LA, Shak S, Jacobs MK, et al: A population-based study of tumor gene expression and risk of breast cancer death among lymph nodenegative patients. Breast Cancer Res 8:R25, 2006
7. Toi M, Iwata H, Yamanaka T, et al: Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 116:3112-3118, 2010
8. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
9. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
10. Gradishar WJ, Anderson BO, Blair SL, et al: Breast cancer version 3.2014. J Natl Compr Canc Netw 12:542-590, 2014
11. Goldhirsch A, Winer EP, Coates AS, et al: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206-2223, 2013
12. Coates AS, Winer EP, Goldhirsch A, et al: Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-1546, 2015
13. Prat A, Cheang MCU, Martín M, et al: Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31:203-209, 2013
14. Dowsett M, Nielsen TO, A'Hern R, et al: Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103: 1656-1664, 2011
15. McCullough AE, Dell'orto P, Reinholz MM, et al: Central pathology laboratory review of HER2 and ER in early breast cancer: An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat 143:485-492, 2014
16. Perez EA, Press MF, Dueck AC, et al: Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 138:99-108, 2013
17. Badve SS, Baehner FL, Gray RP, et al: Estrogenand progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
18. Polley M-YC, Leung SCY, McShane LM, et al: An international Ki67 reproducibility study. J Natl Cancer Inst 105:1897-1906, 2013
19. Andre F, Arnedos M, Goubar A, et al: Ki67-no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol 12:296-301, 2015
20. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008
21. Sparano JA, Gray RJ, Makower DF, et al: Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 33:2005-2014, 2015
22. Penault-Llorca FM, Filleron T, Asselain B, et al: Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial. J Clin Oncol 32, 2014 (suppl; abstr 11052)
23. Bueno-de-Mesquita JM, Nuyten DSA, Wesseling J, et al: The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 21: 40-47, 2010
24. Gluz O, Liedtke C, Peyro Saint Paul HP, et al: The prognostic and predictive impact of genomic grade index (GGI) versus central grade or molecular class in intermediate-risk breast cancer (BC): Results from the EC-Doc trial. J Clin Oncol 31, 2013 (suppl; abstr 1092)
25. Kennecke HF, Speers CH, Ennis CA, et al: Impact of routine pathology review on treatment for node-negative breast cancer. J Clin Oncol 30: 2227-2231, 2012
26. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164-172, 2014
27. de Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504-1513, 2007
28. Nitz U, Gluz O, Huober J, et al: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression. Ann Oncol 25:1551-1557, 2014
29. Viale G, Regan MM, Mastropasqua MG, et al: Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207-212, 2008
30. Luporsi E, André F, Spyratos F, et al: Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Res Treat 132:895-915, 2012
31. Hofmann D, Nitz U, Gluz O, et al: WSG ADAPT-Adjuvant Dynamic Marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: Study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials 14:261, 2013